Sofinnova Investments’s Biogen BIIB Stock Holding History

Sofinnova Investments’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-40,000	Closed	-$9.46M	–	73
2019 Q1	$9.46M	Buy	+40,000	New	+$12.6M	0.91%	23

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sofinnova Investments's BIIB Position: Q2 2026 in Review

Sofinnova Investments sold out of Biogen (BIIB) in Q2 2026, closing a stake of 229,521 shares — an estimated $42.1M sold.

Sofinnova Investments first reported a position in BIIB in Q4 2019 and held it in 6 quarters. The position peaked at $42.1M in Q1 2026. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Sofinnova Investments reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
Sofinnova Investments sold 229,521 Biogen shares in Q2 2026, an estimated $42.1M.
Sofinnova Investments first reported a position in Biogen in Q4 2019 and held it in 6 quarters.
Sofinnova Investments's Biogen position peaked at $42.1M in Q1 2026.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.